Bavarian Nordic and SII sign agreement for chikungunya vaccine production

Bavarian Nordic has signed a manufacturing statement with Serum Institute of India (SII), expanding its strategical concern done a declaration for its chikungunya vaccine (CHIKV VLP).

The declaration covers a afloat exertion transportation for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to summation accumulation capableness and aboriginal proviso for endemic low- and middle-income countries.

The caller statement builds upon the existing licence and manufacturing concern betwixt the 2 companies for the mpox vaccine.

It replaces an earlier woody with Biological E. Both parties volition besides research imaginable co-development opportunities arsenic portion of this extended collaboration.

Bavarian Nordic's president and CEO Paul Chaplin said: “We are pleased to fortify our strategical concern with Serum Institute of India.

"By leveraging the strengths of some organisations, we tin standard manufacturing of our chikungunya vaccine to grow planetary proviso and amended entree for populations astir the globe.”

The CHIKV VLP vaccine is simply a prefilled, single-dose, adjuvanted virus-like particle recombinant macromolecule merchandise intended for progressive immunisation against illness caused by the chikungunya microorganism successful radical aged 12 years and above.

It is designed to trigger a beardown seroresponse, with protective immunity opening to make arsenic soon arsenic 1 week pursuing vaccination.

As it does not incorporate viral familial material, the vaccine is non-infectious and cannot origin disease, making it suitable for a wide colonisation demographic.

Marketed arsenic Vimkunya, CHIKV VLP has received support from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission, and the US Food and Drug Administration (FDA) successful 2025.

Regulatory reappraisal is underway successful Canada and Switzerland.

In September 2025, Bavarian Nordic launched its chikungunya vaccine, Vimkunya, successful the UK.

The motorboat followed a important summation successful travel-related illness cases reported nationwide. The UK Health Security Agency (UKHSA) stated that incidences roseate by 170% successful August 2025 compared with the aforesaid play successful 2024.

"Bavarian Nordic and SII motion statement for chikungunya vaccine production" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.